Subfoveal Choroidal Thickness in Fellow Eyes of Patients with Central Serous Chorioretinopathy

Purpose: This article identifies clinical features that differentiate central serous chorioretinopathy (CSR) from neovascular age-related macular degeneration (nAMD) and uses this information to develop a diagnostic tool. Methods: A prospective observational study was conducted of patients with a new diagnosis of CSR, nAMD, or indeterminate presentation. All patients underwent clinical assessment, axial length measurement, enhanced-depth imaging–optical coherence tomography, and intravenous fluorescein angiography. A final consensus diagnosis was derived following review of these factors. Results: A total of 56 eyes of 56 patients were enrolled (CSR = 34; nAMD = 22). The subfoveal choroidal thickness was greater in the CSR group (421 ± 106 µm) than the nAMD group (219 ± 91 µm, P < .001). The following odds ratio of CSR reached statistical significance: age 70 and younger (72.00, 95% CI: 11.99-432.50), subfoveal choroidal thickness greater than or equal to 300 µm (33.92, 95% CI: 4.06-283.18), dome-shaped neurosensory detachment (13.24, 95% CI: 3.22-54.45), retinal pigment epithelial changes (0.31, 95% CI: 0.10-0.97), subretinal hyperreflective material (0.11, 95% CI: 0.03-0.42), and fibrovascular pigment epithelial detachment (0.05, 95% CI: 0.01-0.47). A stepwise CSR vs nAMD clinical decision-making algorithm is proposed. Conclusions: Choroidal thickness is increased in CSR when compared with nAMD. The presented odds ratios and the CSR vs nAMD clinical decision-making tool can be applied to distinguish CSR from nAMD.

Download Full-text

Change in subfoveal choroidal thickness in central serous chorioretinopathy

Eye ◽

10.1038/eye.2013.164 ◽

2013 ◽

Vol 27 (10) ◽

pp. 1221-1222 ◽

Cited By ~ 3

Author(s):

C S H Tan ◽

K X Cheong ◽

S R Sadda

Keyword(s):

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Subfoveal Choroidal Thickness

Download Full-text

Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy

Graefe s Archive for Clinical and Experimental Ophthalmology ◽

10.1007/s00417-021-05256-3 ◽

2021 ◽

Author(s):

Benedikt Schworm ◽

Jakob Siedlecki ◽

Leonie F. Keidel ◽

Tina R. Herold ◽

Nikolaus Luft ◽

...

Keyword(s):

Laser Treatment ◽

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Subretinal Fluid ◽

Symptom Duration ◽

Macular Function ◽

Chronic Central Serous Chorioretinopathy ◽

Subfoveal Choroidal Thickness ◽

Laser Treatments ◽

Subthreshold Laser

Abstract Purpose There is an ongoing controversial debate about the effectiveness of laser treatments in chronic central serous chorioretinopathy (cCSC). We performed a prospective non-randomized interventional study to learn about the effects of a subthreshold laser treatment (Topcon Endpoint Management™, Topcon Healthcare Inc., Tokyo, Japan) in patients with cCSC. Methods Patients with cCSC and a minimum symptom duration of 4 months were included and treated with a standardized laser pattern covering the macular area. Retreatment was performed every 3 months if persistent subretinal fluid was observed. The primary endpoint was resolution of subretinal fluid at 6 months. Further outcome parameters included best corrected visual acuity, microperimetry, central macular and subfoveal choroidal thickness. Results A total of 42 eyes of 39 patients were included. Mean patient age was 48 ± 10.6 years (range 25–67). Mean symptomatic time before inclusion into the study was 134 ± 133.4 weeks (16–518). Before inclusion, 78.6% of the patients had failed to resolve subretinal fluid under mineralocorticoid receptor antagonists and 14.3% had a recurrence after half-dose photodynamic therapy. Complete resolution of subretinal fluid was observed in 42.9% at 6 months and in 53.8% at 12 months after baseline. Central retinal thickness decreased from 398 ± 135 µm to 291 ± 68 µm (p < 0.001), subfoveal choroidal thickness changed slightly (430 ± 116 µm to 419 ± 113 µm, p = 0.026), microperimetry-derived macular function improved by 19.1 ± 4.7 dB to 21.3 ± 4.8 dB (p = 0.008) and mean BCVA improved by 4.9 ± 8.6 ETDRS letters (p < 0.001). Conclusion The results show that the investigated laser treatment is effective in reducing subretinal fluid and leads to an improvement of functional parameters.

Download Full-text

Choroidal thickness evaluation of healthy eyes, central serous chorioretinopathy, and fellow eyes using spectral domain optical coherence tomography in Indian population

Indian Journal of Ophthalmology ◽

10.4103/0301-4738.194999 ◽

2016 ◽

Vol 64 (10) ◽

pp. 747 ◽

Cited By ~ 5

Author(s):

Supriya Arora ◽

Richa Pyare ◽

Preethi Sridharan ◽

Tarun Arora ◽

Meenakshi Thakar ◽

...

Keyword(s):

Optical Coherence Tomography ◽

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Indian Population ◽

Spectral Domain ◽

Optical Coherence ◽

Thickness Evaluation ◽

Healthy Eyes ◽

Fellow Eyes

Download Full-text

Comparison of Choroidal Thickness in Eyes with Central Serous Chorioretinopathy, Asymptomatic Fellow Eyes and Normal Eyes

Journal of the Korean Ophthalmological Society ◽

10.3341/jkos.2012.53.1.87 ◽

2012 ◽

Vol 53 (1) ◽

pp. 87 ◽

Cited By ~ 4

Author(s):

Joon Hee Cho ◽

So Hyun Bae ◽

Jae Ryong Han ◽

Woo Ho Nam ◽

Ha Kyoung Kim

Keyword(s):

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Fellow Eyes

Download Full-text

Elevated Choroidal Thickness and Central Serous Chorioretinopathy in the Fellow Eyes of Patients with Circumscribed Choroidal Hemangioma

Ocular Oncology and Pathology ◽

10.1159/000486864 ◽

2018 ◽

Vol 4 (6) ◽

pp. 375-380 ◽

Cited By ~ 4

Author(s):

Ryan S. Kim ◽

Rishabh R. Jain ◽

David M. Brown ◽

Maria E. Bretana ◽

Eric N. Kegley ◽

...

Keyword(s):

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Choroidal Hemangioma ◽

Fellow Eyes

Download Full-text

Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2018-312892 ◽

2018 ◽

Vol 103 (8) ◽

pp. 1184-1189 ◽

Cited By ~ 13

Author(s):

Marta Zola ◽

Alejandra Daruich ◽

Alexandre Matet ◽

Irmela Mantel ◽

Francine Behar-Cohen

Keyword(s):

Central Serous Chorioretinopathy ◽

Mineralocorticoid Receptor ◽

Choroidal Thickness ◽

Treatment Initiation ◽

Retinal Pigment ◽

Subretinal Fluid ◽

Chronic Central Serous Chorioretinopathy ◽

Mineralocorticoid Receptor Antagonist ◽

Subfoveal Choroidal Thickness ◽

Imaging Characteristics

AimsTo evaluate the long-term oral mineralocorticoid receptor antagonist (MRa) treatment in chronic central serous chorioretinopathy (CSC).MethodsPatients with chronic non-resolving CSC (defined as foveal subretinal fluid (SRF) lasting >4 months with retinal pigment epithelium (RPE) alterations) treated with MRa only (eplerenone or spironolactone) for at least 6 months were retrospectively included. Clinical and imaging characteristics were recorded during visits at baseline, 6, 12, 18 and 24 months.ResultsSixteen eyes of 16 patients were included (mean age 53±11 years; 14 men, 2 women). Mean duration of SRF before treatment initiation was 11.2±19.7 months. MRa treatment was administered during 21.0±5.1 months (range, 10–24 months). There was a progressive improvement of visual acuity (p=0.05), a decrease of foveal SRF height (p=0.011), central macular thickness (p=0.004) and subfoveal choroidal thickness (p=0.002) over 24 months. Changes in SRF were correlated with subfoveal choroidal thickness at 24 months (p=0.006, Spearman r=065). The mean time to complete foveal SRF resolution was 10.5±8.0 months after treatment initiation. At 24 months, foveal SRF resolution was achieved in 13 eyes (81%). Minor side effects occurred in five patients (31%) and resolved after switching between MRa.ConclusionThe visual and anatomical benefit of MRa treatment prolonged for 6 months or more in chronic, non-resolving CSC appeared to be maintained over a 24-month period. These results suggest that MRa can be proposed as an alternative therapy in severe CSC with advanced RPE alterations.

Download Full-text